Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)

• Sponsor: University Hospital, Caen (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00316576
• Collaborator: (none)
• Enrollment: 160
• Location: 1
• Duration (Months): 6
• Patients Per Site Per Month: 26.5

Study Details

Study Description

Brief Summary

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Condition or Disease	Intervention/Treatment	Phase
Kidney Failure, Acute; Critical Illness	Procedure: Blood sampling for PCR

Detailed Description

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 160 participants
• Time Perspective: Prospective
• Official Title: Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients
• Study Start Date: May 1, 2006
• Actual Study Completion Date: Nov 1, 2006

Outcome Measures

Primary Outcome Measures

1. Incidence of ARF [During ICU stay]

Secondary Outcome Measures

1. Mortality [ICU and Hospital mortality]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age > 18 yrs

• ICU stay > 48 hours

Exclusion Criteria:

• Age < 18 yrs

• Creatinine > 180 µmol/L

• Absence of consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Medical Intensive care Unit; Caen University Hospital	Caen		France	14000

Sponsors and Collaborators

• University Hospital, Caen

Investigators

• Principal Investigator: Damien du Cheyron, MD, University Hospital, Caen

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00316576
• Other Study ID Numbers: 05-130
• First Posted: Apr 21, 2006
• Last Update Posted: Jan 17, 2008
• Last Verified: Jan 1, 2008

• Keywords provided by , ,: Kidney failure, Acute; Genetic Polymorphism; Angiotensin-converting enzyme
• Additional relevant MeSH terms: Renal Insufficiency; Acute Kidney Injury; Critical Illness

Study Results

No Results Posted as of Jan 17, 2008